to BioTechniques free email alert service to receive content updates.
Molecular Biology
Real-Time PCR Reagents
Illumina's real-time PCR reagent portfolio includes a novel, probe-based chemistry for gene expression analysis called NuPCR.
In addition to the NuPCR Reagents, Illumina's qPCR DNA binding dye (DBD) assays for gene expression analysis and qPCR high-resolution melting (HRM) assays for genotyping studies provide researchers with a trio of high-quality, budget-friendly options in the qPCR reagent market. NuPCR is a novel probe-based qPCR technology that is designed to show improved specificity and sensitivity to complex gene targets, as compared to existing qPCR technologies. Leveraging the power of DesignStudio, a personalized, web-based design tool available to Illumina customers, NuPCR allows researchers the ability to quickly build custom multiplexed assays. This unique, easy-to-use software delivers bioinformatically optimized assays, ensuring high PCR efficiencies and assays that work the first time without tedious trial and error optimization. In addition, NuPCR, DBD, and HRM assays are compatible with any real-time PCR instrument platform, offering researchers a wider range of reagent choices to implement on their existing instrumentation.
 
This Product is made by:

About Illumina
Illumina is the leading developer, manufacturer, and marketer of next-generation life-science tools and integrated systems for the analysis of genetic variation and biological function. Using our proprietary technologies, we provide a comprehensive line of products and services that currently serve the sequencing, genotyping, and gene expression markets, and we expect to enter the market for molecular diagnostics. Our customers include leading genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, and biotechnology companies. Our tools provide researchers around the world with the performance, throughput, cost effectiveness, and flexibility necessary to perform the billions of genetic tests needed to extract valuable medical information from advances in genomics and proteomics. We believe this information will enable researchers to correlate genetic variation and biological function, which will enhance drug discovery and clinical research, allow diseases to be detected earlier, and permit better choices of drugs for individual patients.

Illumina, Inc.
9885 Towne Centre Drive
San Diego, CA 92121 USA
1.800.809.4566 toll-free
1.858.202.4566 outside North America
1.858.202.4766 fax
Email: [email protected]
Web site: http://www.illumina.com